---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-005656"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2026-07-20T20:27:24+00:00"
generated_at: "2026-07-20T20:28:06.926217+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma enters $4M ATM equity facility with Aegis Capital

## Summary
- Up to $4M of common stock may be sold at-the-market through Aegis Capital as exclusive agent.
- Aegis receives 3.0% commission on gross proceeds plus expense reimbursement.
- Shares issued under existing S-3 shelf (File No. 333-284142) effective Jan 15, 2025.
- No obligation to sell; Company controls timing and volume via placement notices.
- Agreement can be terminated by either party per its terms.

## SEC filing metadata
- accession: 0001683168-26-005656
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2026-07-20T20:27:24+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316826005656/0001683168-26-005656-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316826005656/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-005656
- JSON: https://secwatch.observer/filing/0001683168-26-005656.json
- Plain text: https://secwatch.observer/filing/0001683168-26-005656.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.